Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals has reported Other Non-Current Assets over the past 6 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.5 million for Q4 2025, up 15.51% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 15.51% YoY), and the annual figure for FY2025 was $1.5 million, up 15.51%.
  • Other Non-Current Assets for Q4 2025 was $1.5 million at Apellis Pharmaceuticals, down from $5.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for APLS hit a ceiling of $5.5 million in Q3 2025 and a floor of $898000.0 in Q2 2025.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2024), compared with a mean of $1.5 million.
  • Peak annual rise in Other Non-Current Assets hit 299.93% in 2025, while the deepest fall reached 32.94% in 2025.
  • Apellis Pharmaceuticals' Other Non-Current Assets stood at $1.6 million in 2021, then fell by 18.55% to $1.3 million in 2022, then decreased by 12.49% to $1.1 million in 2023, then increased by 18.67% to $1.3 million in 2024, then grew by 15.51% to $1.5 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.5 million (Q4 2025), $5.5 million (Q3 2025), and $898000.0 (Q2 2025) per Business Quant data.